Several pharmaceutical companies have developed H3R antagonists/inverse agonists, which weakly (<2-fold) and transiently increase brain histamine levels30, for the treatment of obesity, Alzheimer’s disease and schizophrenia32. Here, HRH3 is linked to obesity due to melanocortin 4 receptor deficiency.